A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Inclusion Criteria: * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale * Have an estimated life expectancy of greater than or equal to (≥)12 weeks * Have adequate organ function * Have received 1-4 prior systemic therapies for locally advanced or metastatic disease * Agree to use medically approved contraceptives during the study and for 3 months following the last study treatment * All females must have a negative serum pregnancy test result, and females of child-bearing potential must have a negative urine pregnancy test result, prior to the first study treatment * Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Must be, in the judgment of the investigator, an appropriate candidate for experimental therapy, and no standard therapy would confer clinical benefit For Part A * Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain tumor) that is advanced or metastatic * For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450 (CYP2D6) poor metabolizer phenotype For Part B * Have advanced or metastatic colorectal cancer, triple negative breast cancer (per American Society of Clinical Oncology-College of American Pathology guidelines), epithelial ovarian cancer, endometrial, soft tissue sarcoma, pancreatic cancer * For TNBC: * Recurrent/refractory Triple Negative Breast Cancer (TNBC) defined as any beast canc…